	T OF HEALTH AND HUMAN SERVICES
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
6000 Metro Drive, Suite 101	3/2/2016-3/23/2016*
Baltimore, MD 21215	FEINUMBER
(410)779-5455 Fax:(410)779-5707	3004514280
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Mr. Simeon Georgiou , Owner/Pharma	cist
FIRM NAME	STREET ADDRESS
Professional Arts Pharmacy	2015 Lord Baltimore Dr
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Baltimore, MD 21244-2558	Compounding Pharmacy

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

(b) (4) HEPA filters are located in the "Clean Room" (ISO 6) in the ceiling above the laminar flow hoods. There are no HEPA filters in the "Gowning Room" (ISO 6). In addition, the air feeding the (b) (4)

The firm

does not do environmental monitoring (b) (4)

OBSERVATION 2

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically,

A) On 03/03/2016 we observed a technician (b) (a) gowning up prior to entering and cleaning the floors in the "Clean Room" which includes (b) (4) laminar flow hoods (ISO 5) used to produce sterile drug preparations, the adjacent "Gowning Room", and the adjacent "Entry Room" (non-classified). The "Entry Room" contains materials used for sterile preparations. We observed the following deficiencies with the firm's gowning practices:

FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 1 OF 6 PAGES
SEE REVERSE	EMPLOYEE(S) SIGNATURE	Djamila Harowaka, USC	DATE ISSUED
OF THIS PAGE		Amic Abrixlein, CO	3/23/2016

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHO	NE NUMBER	DATE(S) OF INSPECTION		
Baltimore, M	rive, Suite 101 D 21215	3/2/2016-3/23/2016* FEI NUMBER		
	5 Fax: (410)779-5707	3004514280		
NAME AND TITLE OF INDIVIDU	AL TO WHOM REPORT ISSUED			
	eorgiou , Owner/Pharmacist			
FIRM NAME STREET ADDRESS Professional Arts Pharmacy 2015 Lord Baltimore Dr				
CITY, STATE, ZIP CODE, COUN		TYPE ESTABLISHMENT INSPECTED		
Baltimore, M	D 21244-2558	Compounding Pharmacy		
 Baltimore, MD 21244-2558 Compounding Pharmacy 1. The technician of the entering and cleaning the floors in the "Clean Room" and "Gowning Room". The same shoe covers and gloves worn in the "Entry Room" were also worn in the "Gowning Room" and "Clean Room". 2. The technician's arms, face, neck, and hair were exposed within the "Clean" and "Gowning" rooms. We observed direct contact of the technician's arms/skin with the plastic curtains used to provide physical separation between the "Clean Room" and "Gowning Room", and between the "Gowning Room" and the "Entry Room". 3. The technician for the entry Room". 4. The technician for the entry Room". 5. The technician for the entry Room". 6. I (DH) observed the processing of sterile, injectable Glycine (60 mg/ml) on 03/08/2016 pursuant to Rx# planeary technician for the technician's face/skin above the mask was exposed. 6. Technician for the glower of the technician's face/skin above the mask was exposed. 7. Technician for the glower of the glower hairnet, and face mask. The glowers and face mask were discarded, but the gown and hairnet were kept in the "Gowning Room" for reuse. The technician's graves that were kept in the "Gowning Room" to the "Entry Room" by passing front facing through the plastic curtains which came into contact with the technician's exposed arms and street clothes. 8. The Technician's exposed arms and street clothes. 9. Technician's exposed arms and street clothes. 9. The technician's facing through the plastic curtains which came into contact with the technician's exposed arms and street clothes. 9. The technician's exposed arms and street clothes. 9. The technician's facing through the plastic curtains which came into contact with the technician's exposed arms and street clothes.				
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	nne Aberteen, CO	DATE ISSUED	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	PECTIONAL OBSERVATIONS	PAGE 2 OF 6 PAGES	

	DEPARTMENT OF H	HEALTH AND HUM	a ser la ser en la companya de la co		
DISTRICT ADDRESS AND PHO	NE NUMBER		DATE(S) OF INSPECTION		
6000 Metro D Baltimore, M	Drive, Suite 101		3/2/2016-3/23/2016*		
	5 Fax:(410)779-5707		3004514280		
	al to whom REPORT ISSUED eorgiou , Owner/Pharmacist	:			
FIRM NAME		STREET ADDRESS			
	Arts Pharmacy		d Baltimore Dr		
CITY, STATE, ZIP CODE, COUN Baltimore, M		TYPE ESTABLISHME	ling Pharmacy		
Darcimore, H	D 21244 2000	compound	ing marmacy		
	ON 3 gned to prevent microbiological ned and followed.	l contamination	of drug products purportin	ng to be sterile	
	bes not monitor the differential pom", "Gowning Room" and "En		en the classified and uncla	ssified areas	
B) Smoke stud	ies are not performed under dyna	amic conditions	5.		
	es not perform environmental r nd unclassified rooms ("Clean R				
D) The firm uses non-sterile (b) (4) and non-depyrogenated (b) (4) to produce sterile drug products.					
E) The firm does not have a standardized procedure for (b) (4) the (b) (4) On 02/25/2016 (b) (4) failure occurred for Prednisolone 50mg/ml injectable (Batch No. A5699). Pharmacist ^{(b) (6), (b) (7)} told us the sterilization failed because the (b) (4) and that they repeated the sterilization (b) (4) . Furthermore, there is no written record of any investigation.					
F) There is no qualification, no calibration or preventive maintenance of the (b) (4) (b) (4)					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	Djamila Anne Abi	Haronaka, cso meen, co	DATE ISSUED 3/23/2016	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL O	BSERVATIONS	PAGE 3 OF 6 PAGES	

	LTH AND HUMAN SERVICES JG ADMINISTRATION
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
6000 Metro Drive, Suite 101	3/2/2016-3/23/2016*
Baltimore, MD 21215	FEI NUMBER
(410)779-5455 Fax: (410)779-5707	3004514280
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Mr. Simeon Georgiou , Owner/Pharmacist	
FIRM NAME	STREET ADDRESS
Professional Arts Pharmacy	2015 Lord Baltimore Dr
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Baltimore, MD 21244-2558	Compounding Pharmacy

OBSERVATION 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.

Specifically,

- A) On 03/03/16 I (DH) observed the technician (7)(c) cleaning the laminar flow hood. I observed the following deficiencies:
 - 1. The technician (b) (6), alternated between cleaning of the interior and exterior surfaces of the hood using the same non-sterile wipe (b) (4)
 - 2. As the cleaning progressed, no additional (b) (4) was added to the wipe. By the completion of the cleaning the surfaces did not appear to be wetted. The working surface of the laminar flow hood is the last surface to be cleaned.
 - 3. Each hood contained a (b) (4) . The top of the (b) (4) was also wiped using the same (b) (4) wipe. The (b) (4) were not moved to wipe the counter underneath.
 4. The top of the horizontal shield of the hood was not cleaned. It was used to place a (b) (4)
 - (b) (4) (b) (4)

5. The firm has not established contact times for the cleaning and disinfecting of surfaces.

6. The firm uses non-sterile (b) (4) wipes to clean the laminar flow hoods.

7. The work area of the laminar flow hoods (b) (4) are constructed of formica.

B) I (DH) observed a white residue and a yellow residue on the stainless steel back of the laminar flow hood (P1). I (DH) observed what appeared to be rust along the left hand side of laminar flow hood (P1).

SEE REVERSE OF THIS PAGE	A A	Anne Abardeen, CO	
AIG	EMPLOYEE(S) SIGNATURE	> Djamila Harowaka, 150	DATE ISSUED 3/23/2016

		OF HEALTH AND HUMAN SERVICES AND DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHO		DATE(S) OF INSPECTION		
	rive, Suite 101	3/2/2016-3/23/2016	5*	
Baltimore, M		FEI NUMBER 3004514280		
(410)779-545	5 Fax:(410)779-5707	5004514200		
NAME AND TITLE OF INDIVIDU	AL TO WHOM REPORT ISSUED			
Mr. Simeon G	eorgiou , Owner/Pharmac:	ist		
FIRM NAME		STREET ADDRESS	\$\$	
	Arts Pharmacy	2015 Lord Baltimore Dr		
CITY, STATE, ZIP CODE, COUN		TYPE ESTABLISHMENT INSPECTED		
Baltimore, M	D 21244-2558	Compounding Pharmacy		
samples are sent out (b) B) The firm pr	 (b) (4) (4) samples from^{(b) (4)} sterile Products sent out for oduces sterile drugs and (b) (At the time of a <i>igerator and 45 days in the f</i> 	oing sterility testing on December 2013 As per the firm's sterility testing e product prescriptions dispensed from (1) r sterility testing are: (b) (4) 4) dispensing a label is added indicating: "o freezer". For example we observed the fo	ng log, they have	
SEE REVERSE	EMPLOYEE(S) SIGNATURE	Djamila Harovaka, LSO Anne Abenteen, CO	DATE ISSUED 3/23/2016	
OF THIS PAGE				

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHO			DATE(S) OF INSPECTION		
Baltimore, M			3/2/2016-3/23/2016* FEI NUMBER		
(410)779-545	5 Fax:(410)779-5707		3004514280		
NAME AND TITLE OF INDIVIDU	AL TO WHOM REPORT ISSUED				
and the state of the state of the state of the state of the	eorgiou , Owner/Pharmacist				
FIRM NAME	sional Arts Pharmacy 2015 Lord Baltimore Dr				
CITY, STATE, ZIP CODE, COUN		2015 Lord Baltimore Dr TYPE ESTABLISHMENT INSPECTED			
Baltimore, M	D 21244-2558	Compounding Pharmacy			
Baltimore, MD 21244-2558 Compounding Pharmacy OBSERVATION 6 Component testing is deficient in that each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality. Specifically, The firm used (b)(4) (non-pharmaceutical grade) for the preparation of prescribed sterile eyes drops. In addition, the main ingredient concentration in (b)(4) [Batch records indicated that the concentration was not adjusted to conform to specifications. *DATES OF INSPECTION 3/02/2016(Thu), 3/07/2016(Mon), 3/08/2016(Tue), 3/18/2016(Fri), 3/23/2016(Wed)					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	Djomila Anne Abe	Harouaka, CSU Macen, (U	DATE ISSUED	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE IN	SPECTIONAL O	BSERVATIONS	PAGE 6 OF 6 PAGES	